financetom
Business
financetom
/
Business
/
EyePoint Gets Positive Recommendation for Wet AMD Trials From Safety Committee
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
EyePoint Gets Positive Recommendation for Wet AMD Trials From Safety Committee
Nov 19, 2025 6:08 AM

08:29 AM EST, 11/19/2025 (MT Newswires) -- EyePoint Pharmaceuticals ( EYPT ) said Wednesday that an independent Data Safety Monitoring Committee has recommended that its ongoing pivotal phase 3 program evaluating Duravyu for the treatment of wet age-related macular degeneration continue as planned without any modifications to the protocol.

Topline data from the trials is expected starting in mid-2026, the company said.

Shares of EyePoint Pharmaceuticals ( EYPT ) were 3.9% higher in recent premarket trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved